Mostrar el registro sencillo del ítem

dc.contributor.authorMuller, Claudia Reginapt_BR
dc.contributor.authorHaas, Sandra Elisapt_BR
dc.contributor.authorBassani, Valquiria Linckpt_BR
dc.contributor.authorGuterres, Silvia Stanisçuaskipt_BR
dc.contributor.authorFessi, H.pt_BR
dc.contributor.authorPeralba, Maria do Carmo Ruaropt_BR
dc.contributor.authorPohlmann, Adriana Raffinpt_BR
dc.date.accessioned2013-07-03T01:42:48Zpt_BR
dc.date.issued2004pt_BR
dc.identifier.issn0100-4042pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/72987pt_BR
dc.description.abstractThe parameters which affect the degradation and stabilization of diclofenac in suspensions of nanocapsules and of the corresponding spray-dried powders were investigated. Formulations were subjected to 14 months of storage at room temperature. In addition, a study of the degradation of diclofenac was carried out by exposing the formulations or mixtures (drug and adjuvants) to UVC wavelengths. The presence of Epikuron 170® in a concentration higher than 3.06 mg/mL stabilizes the drug, avoiding its reduction or degradation. The degradation products were isolated, analyzed by gas chromatography-mass spectrometry, and identified as 2-(2’,6’- dichlorophenyl)aminobenzyl alcohol and N-(2’,6’-dichlorophenyl)anthranilylaldehyde.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoporpt_BR
dc.relation.ispartofQuímica nova. São Paulo. Vol. 27, n. 4 (2004), p. 555-560pt_BR
dc.rightsOpen Accessen
dc.subjectNanoparticlesen
dc.subjectDiclofenacopt_BR
dc.subjectDiclofenacen
dc.subjectNanocápsulaspt_BR
dc.subjectDegradationen
dc.subjectDegradaçãopt_BR
dc.subjectFarmacologiapt_BR
dc.titleDegradação e estabilização do diclofenaco em nanocápsulas poliméricaspt_BR
dc.title.alternativeDegradation and stabilization of diclofenac in polymeric nanocapsules en
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000424352pt_BR
dc.type.originNacionalpt_BR


Ficheros en el ítem

Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem